RFA-CA-27-016: The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)

RFA-CA-27-016: The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)

This NOFO is one of the few cancer trial opportunities in 2026 that combines three things at once: (1) a clearly defined disease-advancing mandate, (2) a real network execution model, and (3) high scrutiny on trial conduct. It is aimed at institutions that can carry the operational and scientific weight of being a Lead Academic Organization (LAO) inside the National Cancer Institute’s Experimental Therapeutics Clinical Trials Network (ETCTN).

The announcement is active with a posted date of May 08, 2026, earliest submission date of May 30, 2026, a key due date of June 30, 2026, and an expiration date of July 01, 2026. In practical terms, teams should treat this as a near-term filing window for FY 2027 planning rather than a broad recurring annual cycle in this specific NOFO.

Key details at a glance

Why this opportunity is structurally different

A lot of research grants ask for a strong proposal and good outcomes. This one asks for something closer to a delivery system. ETCTN LAOs must do more than run a protocol. They are expected to build and govern the institutional and member-site machinery needed to identify requests for trials, develop protocols, conduct them under CTEP/IND rules, and deliver results in a way that can be measured through accrual, activation, and trial completion quality.

The NOFO repeatedly frames LAO work as team-science infrastructure rather than isolated investigator projects:

• design and run early phase trials under NCI DCTD/CTEP IND agents;
• use centralized resources (such as ETCTN pharmacokinetics and support systems);
• maintain a roster of clinical sites and monitor accrual and performance;
• actively support young investigators through mentorship.

This is why this opportunity has strategic value for organizations that already sit near clinical trial infrastructure but lack a formal NCI-network leadership role. The funding is not for a pilot experiment in a lab. It is for an operational clinical research leadership posture that can repeatedly absorb compounds, run trials, and maintain compliance.

The mechanism is a UM1 cooperative agreement, so NIH is not just a reviewer and payer. NIH staff can and do remain significantly involved in oversight and coordination after award. That matters for PI strategy because applicants should design governance and admin structures that can coexist with federal scientific input and reporting expectations.

What this call funds (and what it does not)

This NOFO supports a Lead Academic Organization as part of a national trial network. In practical terms, the resources should support:

• a leadership core responsible for strategic coordination, management, and accountability;
• a clinical trial development and operations core for design, conduct, and statistical quality;
• a member-site accrual and performance core that tracks site enrollment and execution;
• operational collaboration with other LAOs in ETCTN.

The LAO is evaluated on its capacity to bring in and complete delayed-onset early-phase trials (phase 0, phase 1, phase 2, and pilot work), and to sustain trial quality across multiple IND-sourced agents. This is a very specific functional demand. You are not proposing one one-off intervention and hoping trial volume appears later; you are proposing a functional platform for sustained clinical research delivery.

Important boundary: applications do not propose specific fixed trials at submission. The NOFO explicitly directs that, because the review is for LAO capability and readiness. That does not mean absence of scientific specificity is acceptable. Proposals are still judged by the quality of the implementation model and expected performance standards.

The amount is not set by a single fixed total budget cap. The page states, “Application budgets are not limited.” But NIH reviews still demand realistic costing linked to actual program activities, not aspirational spending.

Eligibility and who this is for

This opportunity is broader than a traditional university-only framing. The eligibility section includes higher education, several nonprofit and government categories, and also for-profit and federal entities. In addition, for administrative purposes, a non-U.S. entity pathway exists in NIH systems, while the core LAO definition emphasizes organizations in the U.S. or Canada that provide direct medical care and operate as a single financial/governance entity.

That combination produces a nuanced fit rule:

• if your institution is the kind of cancer center that can coordinate multi-site accrual, handle IND-linked early-phase governance, and sustain compliance workflows, it may be structurally eligible;
• if your team is strong in science but weak in operations, it may still fail at implementation-focused review.

The PI layer is also important. Even though many senior investigators can be involved, the NOFO repeatedly pushes for trials led by or including early career clinical investigators (ECIs), with mentor structures required. That is not a symbolic clause: the network expects mentorship as part of mission outcomes.

Another important point: one application per institution is allowed for this announcement. If a large academic enterprise has overlapping divisions, teams must align internally before submission.

How applications are reviewed: what reviewers actually care about

The NOFO review section follows the usual NIH framework but applies it in a way that favors execution quality in a clinical network setting.

You should prepare around four buckets:

1. Strategy and feasibility of the program

   • Are the proposed cores and operations coherent?
   • Can the LAO describe a realistic accrual strategy and escalation path for late-start issues?
   • Is trial initiation timing plausible given staffing and infrastructure?

2. Human subject and safety governance

   • Even though trial details are not proposed up front, your safeguards framework is. You must show controls for risk, data safety monitoring, adverse event workflows, inclusion planning, and trial readiness.

3. Operational execution evidence

   • Reviewers check whether your plans match the responsibility set: site activation, protocol and data workflows, trial monitoring, and reporting cadence.

4. Institutional fit and mentoring value

   • Evidence that the organization can sustain early stage clinical investigator leadership, especially through mentor/mentee structures tied to trial operations.

The NOFO guidance explicitly mentions review of:

• study design and analyses,
• handling of weaknesses and contingencies,
• benchmark setting and feasibility,
• inclusion and protection requirements where applicable,
• timeline realism,
• and enrollment strategies.

A frequent mistake is to over-index on aspirational science and under-index on operational mechanics. Reviewers are repeatedly looking for whether this LAO can carry the operational burden of ETCTN participation over time.

Application materials and submission specifics

The announcement requires standard NIH application structures plus NOFO-specific instructions. The practical structure is best handled as a compliance architecture, not an academic writing exercise:

• R&R Personal Statement / biosketch alignment: use this to show leadership in trial operations and prior early-phase readiness.
• Specific Aims: include expected number of delayed-onset clinical trials by phase and accrual benchmarks.
• Research Plan: organize around the mandated subsections, including:
  • Overview (vision and trial strategy);
  • Organizational Structure and Management Core;
  • Clinical Trial Development & Operations Core;
  • Member Site Accrual and Performance Core;
  • (Renewal only) progress report coverage over required historical period;
• Resource Sharing / dissemination sections where applicable;
• Consortium and contractual arrangements if affiliated organizations are part of the proposal;
• Letters of support demonstrating institutional commitment and network-level readiness.

Because the submission is clinical-trial heavy, systems readiness is part of content quality:

• complete registrations in SAM, eRA Commons, and Grants.gov;
• UEI and CAGE/NCAGE where applicable;
• clear PI and signing official separation in systems;
• ORCID linkage for all PD(s)/PI(s).

Required submission path must be one of:

• NIH ASSIST,
• S2S via institutional route,
• Grants.gov Workspace.

Use one method consistently and test submission windows before the final due time because this NOFO enforces a hard 5:00 PM local-time due date and no late applications.

Timeline interpretation for teams starting in 2026

The posted timeline is compressed. For planning, assume the following sequence:

• May 8, 2026: NOFO visible; confirm you have the latest version.
• May 30, 2026: earliest allowed submission window.
• June 30, 2026: primary due date with no extensions for late filings.
• November 2026: scientific review window and program advisory review windows start to close the cycle.
• January 2027 / April 2027: earliest start and award follow-on milestones.
• July 1, 2026: NOFO expiration.

Given this, your critical internal deadline should be at least one to two weeks before June 30. It sounds extreme, but with NIH systems, late registration glitches and incomplete institutional clearances are common causes of failed first submissions.

If your team already uses NIH clinical trial infrastructure, this could still be useful if your objective is to scale from leading individual trials to coordinating multiple trials with central oversight across affiliated sites.

Preparing a strong LAO narrative: a practical guide

A competitive application for this NOFO should prove three things in sequence:

1. We can lead trials, not only run them

   Build explicit operating plans for protocol intake, committee review, protocol development support, and centralized monitoring. Map every major task to the names of responsible units, timelines, and dependencies. If a task has no owner, reviewer confidence drops quickly.

2. We can maintain trial quality under pressure

   Show how you will detect and correct accrual shortfalls, protocol delays, and site underperformance. Include escalation triggers and response plans. If accrual management is described only in principle, it reads as unprepared. If it is written as an explicit operating model with KPIs, it reads as feasible.

3. We can support career development and network behavior change

   The NOFO expects mentorship of early-career clinical investigators (ECIs) as a recurring mission, not an optional side program. Include mentoring structure, assignment expectations, and role clarity across PI, mentors, and early-career leads.

A fourth but hidden success factor is interoperability with NCI systems: your team must show familiarity with CTEP IND requirements, OPEN/CTSU workflows, data capture expectations, and biospecimen/repository handling where relevant.

Common errors to avoid

1. Confusing mechanism scope

   Some teams draft a purely scientific protocol concept and underplay the role of the LAO as a coordinated entity. That is likely to be judged weak because this NOFO is about organizational leadership.

2. Underestimating registrations and role setup

   It is common to discover incomplete SAM/eRA/Grants.gov registrations in the final week. Fix this first, not last.

3. Ignoring timeline realism

   Budgets can scale to needs, but review still rewards feasibility. If your accrual assumptions cannot justify staffing and data workflows, it is viewed as optimistic storytelling rather than planning.

4. Treating mentorship as narrative fluff

   Mentorship obligations are explicit in the operational model. Teams should provide clear mentor commitments and evidence that the structure is active, not aspirational.

5. Inconsistent clinical-trial compliance language

   For NIH-defined clinical research, human subjects and safety narratives must be internally consistent across forms and sections. Inconsistency between Specific Aims, human subjects plans, and study administration plans commonly causes review concerns.

FAQ for quick decision-making

Is this still open?

As of the checked date (2026-05-31), this NOFO is open through its stated cycle and expires on 2026-07-01. The key date is June 30, 2026 submission due.

Can foreign institutions apply?

The NOFO includes non-U.S. organizational pathways, but for this mechanism the core LAO definition highlights academic centers in the U.S. or Canada. That means you should validate the exact structure and location of your application entity against the administrative instructions before drafting.

Can our institution submit more than one application?

The NOFO states only one application per institution is allowed.

Do I need to propose specific trial protocols?

The announcement is designed so applicants do not propose specific trials at submission. The review focuses on readiness and capability to lead a portfolio of ETCTN trials and associated trial-management systems.

Do awards have a fixed budget ceiling?

No fixed budget ceiling is specified in the NOFO text. Budgets must reflect actual needs and should be justified by program operations, not inflated for flexibility.

Are late applications accepted?

No. Late applications are not accepted. Submission systems and NIH compliance should be finalized before the 5:00 PM local-time deadline.

What makes this a high-trust fit versus a vanity fit

The best applicants for this call usually have three overlapping strengths: trial experience, operational discipline, and leadership structure. A team with excellent investigators but weak trial administration is risky; a team with strong admin support but weak scientific identity is also weak; a balanced group that shows both has the strongest position.

This NOFO is especially relevant if your institution is already participating in oncology trial networks and now wants to move up-level from individual participation toward network leadership. It is less relevant for teams pursuing single-lab therapeutics research without broad trial infrastructure.

Official sources and next steps

• Read the official NOFO text (official source URL): https://files.simpler.grants.gov/opportunities/78a9c523-d495-4606-a9c2-b67724d68434/attachments/f12fae34-6c5b-4be8-8b35-794d43edbdc4/RFA-CA-27-016-Full-Announcement.html
• Confirm application instructions through the NIH How to Apply Guide and the relevant NOFO section references before drafting core attachments.
• For implementation questions, use the official ETCTN and NCI contact pathway listed in the NOFO, including [email protected] for scientific/program questions.

If your institution is a realistic LAO candidate, the practical next move is to lock a two-week internal writing sprint around these priorities:

1. governance map,
2. accrual operations plan,
3. mentoring model,
4. trial-readiness evidence,
5. compliance checklist.

That is the minimum set that separates a compliant filing from a competitive one in this call.